Nuvation Bio (NYSE:NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a "buy" rating on the stock.
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]
Lenz Therapeutics: A Close Look [Seeking Alpha]
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]